Fred J. Ansfield

Last updated

Fred Joseph Ansfield, M.D. (1910 - 1996) was an American pioneer of medical oncology. He was a leader in applying 5-FU (5-Fluorouracil) to humans, demonstrating its effectiveness as a chemotherapy drug. [1] [2] Ansfield co-founded the American Society of Clinical Oncology (ASCO) in 1964, along with Harry Bisel, Arnoldus Goudsmit, Herman H. Freckman, Robert W. Talley, William Wilson and Jane Cooke Wright. [3]   He served as ASCO's third president (1966-1967). [4]

Contents

Dr. Fred J Ansfield Photo of Fred J Ansfield.jpg
Dr. Fred J Ansfield

"He shall be remembered by cancer treatment specialists everywhere as one of the founders of Medical Oncology." [1]

Early life

Ansfield was born on August 30, 1910, in Milwaukee, Wisconsin. By age 13, both of his parents had died from cancer, steering him towards medicine and cancer research. [5] He attended the University of Wisconsin, receiving his Bachelor's degree in 1931. During this period he first had the idea to use mice to find a cure for mammary cancer in animals. [6]

Ansfield received his M.D. in 1933 from the University of Wisconsin Medical School. After his internship and residency training at Milwaukee County Hospital, Ansfield became a camp physician for the Civilian Conservation Corps near Glidden, Wisconsin. He entered private practice there in 1936, with the goal of saving enough money to fund his mouse experiments. [6] During World War II, Ansfield served in the U.S. Army Medical Corps as a battalion surgeon for the 11th Airborne division in the Philippines and New Guinea. He earned the Bronze Star, Silver Star and Purple Heart. [5] After the war, he returned to practice in Glidden, Wisconsin. [5]

In 1952 Ansfield began discussing the idea of using the immune system in cancer therapy with his former medical school classmate, Dr. Harold Rusch, then head of the McArdle Memorial Laboratory at the University of Wisconsin. [1] Dr. Rusch helped Dr. Ansfield get started with mouse surgery experiments by providing lab space and equipment. Drs. Ansfield and Rusch designed and began a series of immunotherapy experiments for testing tumors in mice. [1] [7]

In 1957, Dr. Ansfield joined the University of Wisconsin's faculty in an instructor position in the clinical oncology division of the Department of Surgery. [8] [9] [10] His first faculty assignment was testing 5-FU (5-Fluorouracil), a new drug conceptualized and developed by Professor Charles Heidelberger of the McArdle Laboratory. [1] "It was just after he arrived here [Madison] that Dr. Ansfield proposed that dosages of a new drug, 5-Fluorouracil, be increased in the treatment of incurable cancer to find if it had more value than was generally believed". [6]

"Dr. Ansfield found that 5-FU was effective against advanced colon cancer, a disease that defied other treatments. He performed clinical trials to develop protocols that maximized the therapeutic actions of 5-FU while minimizing the drug’s damage to normal tissues. These became the national standard for the use of 5-FU, which is still among the drugs in treatment mixtures for a variety of advanced cancer types." [1]

By 1963, Dr. Ansfield had published a dosage regimen that provided safer application of 5-FU with less discomfort to patients. [7]

"One of the important early discoveries at UW Hospitals was the discovery of the clinical usefulness of 5-FU by Drs. Heidelberger, Fred Ansfield, '33, and Anthony R. Curreri, '33" said Dr. Robert O. Johnson, acting director of the clinical oncology division, Wisconsin Clinical Cancer Center. [11]

"Heidelberger’s work with Dr. Curreri, the Director of the Cancer Hospital, and Dr. Fred Ansfield demonstrated its clinical efficacy in cancer treatment and revolutionized the field of chemotherapy. [12]

In Dr. Ansfield's book(s), he describes chemotherapeutic approaches in treating approximately 4000 cancer patients over a 15 year period. [13]

On May 19, 1985, Dr. Ansfield received the Emeritus Faculty Award from the Wisconsin Medical Alumni Association for his pioneering chemotherapy work. [8]

The American Society of Clinical Oncology's charitable organization, Conquer Cancer Foundation, granted a 'Fred J. Ansfield, MD Endowed Young Investigator Award' in 2017. [14]

Publications

Author or co-author of 125 professional publications including abstracts, articles, chapters and books including:

Related Research Articles

Chemotherapy Treatment of cancer using drugs that inhibit cell division or kill cells

Chemotherapy is a type of cancer treatment that uses one or more anti-cancer drugs as part of a standardized chemotherapy regimen. Chemotherapy may be given with a curative intent, or it may aim to prolong life or to reduce symptoms. Chemotherapy is one of the major categories of the medical discipline specifically devoted to pharmacotherapy for cancer, which is called medical oncology.

Fluorouracil (5-FU), sold under the brand name Adrucil among others, is a chemotherapy medication used to treat cancer. By injection into a vein it is used for colon cancer, esophageal cancer, stomach cancer, pancreatic cancer, breast cancer, and cervical cancer. As a cream it is used for actinic keratosis, basal cell carcinoma, and skin warts.

Oxaliplatin

Oxaliplatin, sold under the brand name Eloxatin, is a cancer medication used to treat colorectal cancer. Often it is used together with fluorouracil and folinic acid (leucovorin) in advanced cancer. It is given by injection into a vein.

Matuzumab is a humanized monoclonal antibody for the treatment of cancer. It binds to the epidermal growth factor receptor (EGFR) with high affinity. The mouse monoclonal antibody (mAb425) from which matuzumab was developed at the Wistar Institute in Philadelphia, Pennsylvania

Harry F. Bisel, M.D. (1918–1994) was an American oncologist. With Fred Ansfield, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane Wright, was one of the founding members of the American Society of Clinical Oncology (ASCO). This group of pioneering doctors, through the formation of ASCO, is largely credited with the development of modern American clinical oncology. In 1964, Bisel was elected the first president of ASCO. He was active in the American Cancer Society and was a consultant to the National Cancer Institute. Bisel was a founding member of the American Society of Preventive Oncology as well as the American Association for Cancer Education.

Tegafur/uracil is a chemotherapy drug combination used in the treatment of cancer, primarily bowel cancer. It is also called UFT or UFUR.

Jane C. Wright American cancer researcher

Jane Cooke Wright was a pioneering cancer researcher and surgeon noted for her contributions to chemotherapy. In particular, Wright is credited with developing the technique of using human tissue culture rather than laboratory mice to test the effects of potential drugs on cancer cells. She also pioneered the use of the drug methotrexate to treat breast cancer and skin cancer.

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.

Carmofur

Carmofur (INN) or HCFU (1-hexylcarbamoyl-5-fluorouracil) is a pyrimidine analogue used as an antineoplastic agent. It is a derivative of fluorouracil, being a lypophilic-masked analog of 5-FU that can be administered orally.

Semustine

Semustine is a drug used in chemotherapy. It is structurally similar to lomustine, being distinguished from it only by an additional methyl group. It has been taken off the drug market for investigation of its cancerous effects, rated as IARC Group 1 carcinogen or a known carcinogen.

McArdle Laboratory

The McArdle Laboratory for Cancer Research is a basic cancer research facility located on the University of Wisconsin–Madison campus in Madison, Wisconsin. It houses the university's Department of Oncology. The staff of the McArdle Laboratory numbers approximately 200. Twenty-eight faculty members lead research groups focused on various fields such as cancer virology, signal transduction, cell cycle, cancer genetics, and carcinogenesis.

John E. Niederhuber

John E. Niederhuber, MD was the 13th director of the National Cancer Institute (NCI), from 2006 until July, 2010, succeeding Andrew von Eschenbach, who went on to become a director at biotechnology firm BioTime. A nationally renowned surgeon and researcher, Dr. Niederhuber has dedicated his four-decade career to the treatment and study of cancer - as a professor, cancer center director, National Cancer Advisory Board chair, external advisor to the NCI, grant reviewer, and laboratory investigator supported by NCI and the National Institutes of Health. He is now Executive Vice President/CEO Inova Translational Medicine Institute and Inova Health System and Co-Director, Johns Hopkins Clinical Research Network.

Wafik El-Deiry is an American physician and cancer researcher who is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, Brown University and the Director of the Joint Program in Cancer Biology at Brown University and its affiliated hospitals. He was previously Deputy Director of Translational Research at Fox Chase Cancer Center, where he was also co-Leader of the Molecular Therapeutics Program.

University of Wisconsin Carbone Cancer Center

The University of Wisconsin Carbone Cancer Center (UWCCC) holds the unique distinction of being the only comprehensive cancer center in Wisconsin, as designated by the National Cancer Institute (NCI), the lead federal agency for cancer research. It is an integral part of both the University of Wisconsin (UW) and the University of Wisconsin Hospital and Clinics. It is located in Madison, Wisconsin.

Wolfram Samlowski

Wolfram Samlowski is a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN) and a member of the Research Developmental Therapeutics and Genitourinary Committees for US Oncology. His research interests include translational research and development of novel cancer immunotherapy agents, translational drug development as well as gene therapy. His clinical interests are in developing more effective treatments for advanced stages of melanoma and non-melanoma skin cancers, and renal cancer.

George Bosl is an American cancer researcher, holder of the Patrick M. Byrne Chair in Clinical Oncology at the Memorial Sloan-Kettering Cancer Center in New York City, and is a Professor of Medicine at the Weill Cornell Medical College. In 1997 he was appointed chair of the Department of Medicine at Sloan-Kettering.

Professor Minesh P Mehta, MD, FASTRO, is an American radiation oncologist and physician-scientist of Indian origin, Ugandan birth, Zambian Schooling and American Training, who contributed to the field of oncology for more than two and half decades.

Pembrolizumab

Pembrolizumab is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer. It is given by slow injection into a vein.

FOLFIRINOX is a chemotherapy regimen for treatment of advanced pancreatic cancer. It is made up of the following four drugs:

References

  1. 1 2 3 4 5 6 Mehta, Minesh P.; Paliwal, Bhudatt R.; Clifton, Kelly H. "MEMORIAL RESOLUTION OF THE FACULTY OF THE UNIVERSITY OF WISCONSIN-MADISON ON THE DEATH OF PROFESSOR EMERITUS FRED JOSEPH ANSFIELD". University of Wisconsin Knowledgebase. University of Wisconsin. Retrieved 14 March 2019.
  2. ↑ ANSFIELD, FJ; SCHROEDER, JM; CURRERI, AR (July 28, 1962). "Five Years Clinical Experience with 5-Fluorouracil". JAMA. 181 (4): 181, 295–9. doi:10.1001/jama.1962.03050300015003. PMID   13861733 . Retrieved 14 March 2019.
  3. ↑ "Founders". ASCO. Retrieved 14 March 2019.
  4. ↑ "Past Presidents". ASCO. Retrieved 13 March 2019.
  5. 1 2 3 Knoche, Eldon (May 4, 1996). "Physician Ansfield was a Pioneer in the Treatment of Cancer". Milwaukee Journal Sentinel.
  6. 1 2 3 "Know Your Madisonian: Dr. Ansfield". Wisconsin State Journal. May 19, 1963. Retrieved 14 March 2019.
  7. 1 2 "Cancer Treatment Pioneer Looks at Progress". Wisconsin Medical Alumni Journal. 17 (3): 11. Summer 1977 – via MINDS@UW.
  8. 1 2 "Dr. Fred Ansfield Receives Emerites Faculty Award". Glidden Enterprise. June 12, 1985.
  9. ↑ "1985 Emeritus Faculty Awards". Wisconsin Medical Alumni Quarterly. 25–2: 4–5. Spring 1985 – via MINDS@UW.
  10. ↑ Daniels, Einar (November 1957). "Alumni Scene". Wisconsin Medical Alumni Journal. II (2): 4 – via MINDS@UW.
  11. ↑ Hurley, Susan (Spring 1976). "Progress in Research, Treatment". Wisconsin Medical Alumni Journal. 16 (2): 2 – via MINDS@UW.
  12. ↑ "UWCCC FROM 1930 – 1970". Carbone Cancer Center. Retrieved March 15, 2019.
  13. 1 2 Ansfield, Fred J (1973). Chemotherapy of Malignant Neoplasms (Second ed.). Springfield, Illinois: Charles C Thomas. ISBN   0-398-02570-3.
  14. ↑ "Conquer Cancer Foundation of ASCO Awards $5.65 Million to Support Cancer Research". myconnection.asco.org. May 30, 2017. Retrieved March 19, 2019.
  15. ↑ Curreri, A. R.; Ansfield, Fred J.; McIver, Forde A.; Waisman, Harry A.; Heidelberger, Charles (May 1, 1958). "Clinical Studies with 5-Fluorouracil" (PDF). Cancer Research. 18 (4): 478–484.
  16. ↑ Ansfield, Fred J (1966). Chemotherapy of Disseminated Solid Tumors. Charles C Thomas.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.